Prime Medicine PRME Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Prime Medicine’s reported figures.
Based on trailing twelve months.
The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Prime Medicine's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Prime Medicine's return on equity?
- Prime Medicine (PRME) reported return on equity of -216.1% in Q1 2026.
- How has Prime Medicine's return on equity changed year-over-year?
- Prime Medicine's return on equity decreased by 87.5% year-over-year, from -115.2% to -216.1%.
- What is the long-term trend for Prime Medicine's return on equity?
- Over 2 years (2023 to 2025), Prime Medicine's return on equity has grown at a 29.0% compound annual growth rate (CAGR), from -88.2% to -146.8%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.